17 filings
8-K
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
8-K
MLYS
Mineralys Therapeutics Inc
4 Apr 24
Departure of Directors or Certain Officers
8:04am
8-K
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
8-K
MLYS
Mineralys Therapeutics Inc
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
MLYS
Mineralys Therapeutics Inc
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
kr1sgyf2 ug40
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
xji5wjgwciuhv22bi
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
8rzdf4 yzi9mw4zqs
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
pbq9zbzq6 yi
2 Nov 23
Regulation FD Disclosure
10:06am
8-K
w2k 2xue1
14 Sep 23
Departure of Directors or Certain Officers
4:11pm
8-K
uds9th4h
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
tal83hkdapbj7yhplf
17 Jul 23
Regulation FD Disclosure
4:03pm
8-K
tdel03vzv yxu
15 May 23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
1qyp5nz6e3
2 May 23
Other Events
8:09am
8-K
70fsim5iowm1bgyr9t
21 Mar 23
Departure of Directors or Certain Officers
7:22pm
8-K
710hz ybl
15 Mar 23
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
fjhh12xr0d8rast8y
14 Feb 23
Amendments to Articles of Incorporation or Bylaws
4:00pm
- Prev
- 1
- Next